IDO1
Indoleamine 2,3-dioxygenase 1
As of the edition of 20 October 2026, IDO1 (indoleamine 2,3-dioxygenase 1, UniProt P14902) has 6 drugs tested at it and 9 companies on the list, 8 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P14902
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 85
- Disease areas
- Cancer; Lungs and airways; Urinary and reproductive; Pregnancy and women's health; Digestive system; Hormones; Skin and connective tissue; Blood and lymph
- Registered trials of its drugs
- 88
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 2 |
| Stopped | 4 |
| Total | 6 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Epacadostat | Stopped | Phase 3 | none listed |
| Linrodostat | Stopped | Phase 3 | none listed |
| Navoximod | Stopped | Phase 1 | none listed |
| DN1406131 | Went quiet | Phase 1 | none listed |
| HTI-1090 | Went quiet | Phase 1 | none listed |
| PF-06840003 | Stopped | Phase 1 | none listed |
6 of 6 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 8 |
| Undetermined | 1 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Incyte | Route A |
| Bristol Myers Squibb | Route A |
| Merck & Co. | Route A |
The other 6 companies at IDO1
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at IDO1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.